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Methods: In this study, we included 141 patients from HF clinics in three hospitals in Taiwan
from October 2008 to December 2010. Nurse case managers at each of the participating sites
registered case report forms (CRFs) for patients during clinic visits. DRPs were classified using
the Pharmaceutical Care Network Europe Foundation (PCNE) classification system and docu-
mented by pharmacists after reviewing CRFs and participating in multidisciplinary team
discussions.
Results: For 141 clinic participants, the average duration of medication use was 17 months,
and 796 DRPs were reported. The DRPs most frequently recorded were the need for laboratory
tests (32.7% of total DRPs), followed by potential interaction (29.6%), nonallergic side effects
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causing a DRP were angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers,
diuretics, warfarin, spironolactone, and b-blockers. The incidence rates of total DRPs was
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336 W.-T. Hsu et al.Conclusion: In Taiwan where the clinical pharmacist system is not well organized, HF outpa-
tients still had a high prevalence of DRPs despite intensive monitoring by nurse case managers.
Clinical pharmacists play critical roles in detecting potential DRPs during long-term medication
treatment for this population.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
A drug-related problem (DRP) is defined as an event or a
circumstance involving drug therapy that actually or
potentially interferes with desired health outcomes.1
Strong evidence has shown that the negative outcomes
associated with DRPs are a major health issue. A probability
model has been used to estimate that morbidity and mor-
tality associated with DRPs account for $76.6 billion in
hospital costs, 17 million emergency department visits, and
8.7 million hospital admissions annually in the United
States.2 The majority of hospital admissions and emergency
department visits caused by DRPs are preventable, and an
effective medication review for the successful detection of
DRPs remains an unmet clinical need.
Heart failure (HF) is a global epidemic that affects
approximately 6% of people aged between 60 and
86 years.3e6 It accounts for considerable morbidity, mor-
tality, and health expenditure. The incidence of HF in-
creases twofold for each decade of life.7 The personal,
economic, and health care burden of HF is expected to
increase in the future as longevity improves, placing further
pressure on finite health care resources. Furthermore,
polypharmacy and older age have been identified as critical
risk factors for DRPs,8,9 and these characteristics are pre-
sent in HF patients. Roughead et al10 demonstrated that a
practitionerepharmacist collaborative review of home
medication is effective in delaying the time to next hospi-
talization in HF patients. Several studies also provided ev-
idence on the clinical effectiveness of pharmacist
intervention in improving medication adherence11 and
controlling of comorbidities of HF patients.12 Therefore, a
comprehensive medication review should be applied in HF
care settings to reduce the incidence of DRPs.
To improve the outcomes of HF patients, the care of
these patients should be integrated in multidisciplinary
management programs, in which patients receive care from
practitioners with expertise in HF.13 These programs are
typically led by a case management nurse, and in-
terventions include education of the patient and family, a
prescribed diet, social service consultation, a review of
medication, and intensive follow up. In practice, most HF
patients are treated as outpatients, and their care in this
setting is challenging; less time is available for outpatient
evaluation, and much more reliance is placed on tele-
monitoring and phone contact between clinic visits. These
clinical scenarios may increase the frequency of DRPs.
Therefore, a multidisciplinary approach is warranted for
the treatment of HF patients in outpatient clinic settings.
The characteristics of DRPs may differ between HF in-
patients and outpatients. For example, outpatients withchronic HF may have DRPs that are more closely related to
comorbidities than to the specific HF syndrome.14 However,
little is known about the incidence and characteristics of
DRPs in outpatients under the care of physicians and nurse
practitioners.
In Taiwan, cardiovascular disease was the second most
prevalent cause of death in 2014. The prevalence of HF is
5.5%15 in Taiwan, a rate comparable to that in other
countries. The medical resources and health care environ-
ment for HF patients differ between Taiwan and Western
countries. The majority of residents in Taiwan are covered
by the country’s National Health Insurance program, in
which patients can visit medical specialists directly without
referral by family physicians. Therefore, unlike in the
United States and Europe, the physicians in charge of the
primary care of HF patients are typically cardiologists
instead of general physicians. The DRP patterns and the
capacity for interventions by pharmacists in the patients
actively seeking medical care in Taiwan remain to be
clarified.
In the current study, we assessed the incidence and
characteristics of DRPs in HF outpatients in multidisci-
plinary management programs led by cardiologists and
nurse case managers. A certified pharmacist retrospectively
reviewed medication taken by patients and recorded DRPs.
The purpose of this study is to evaluate the need for in-
clusion of a clinical pharmacist in multidisciplinary care of
HF outpatients and provide suggestions for implementation
of similar services in Taiwan.
Methods
Setting
Consecutive patients were enrolled from HF outpatient
clinics of Keelung Chang Gung Memorial Hospital, Chi Mei
Hospital, and China Medical University Hospital in Taiwan
between October 2008 and December 2010. This study was
approved by the institutional review boards of the partici-
pating hospitals. The HF clinics were additionally staffed by
nurse specialists who were responsible for case manage-
ment, scheduled telemonitoring, and communication with
pharmacists.
Participants
Patients were eligible if they exhibited HF signs and
symptoms and a low left ventricular ejection fraction
(LVEF  40%) or preserved LVEF with evidence of structural
heart disease, as shown in cardiovascular imaging,
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stable hemodynamic status under standard pharmaco-
therapy for HF. Eligible patients were asked to provide
informed consent. Patients were excluded from the study if
they were not expected to survive for 1 year or were
scheduled for heart transplantation within 1 year.
Data collection
A standard case report form (CRF) was used for data
collection. The form was designed, tested, and found to
be applicable for the participating departments. Patients
referred internally or by primary care physicians under-
went electrocardiography, chest radiography, and cardiac
ultrasonography before screening for participation. All
clinical data of enrolled patients were recorded on CRFs at
the time of or shortly after each clinic visit. Data on pa-
tients’ demographic factors, etiology of HF with inter-
vention history, echocardiographic parameters, New York
Heart Association functional class, and comorbidity were
collected. In addition, body weight, heart rate, blood
pressure, and laboratory findings (e.g., serum urea,
creatinine and electrolyte measurements, and blood
count) were recorded. At each clinic visit, patients were
directly questioned regarding the number of cigarettes
smoked per day and the units of alcohol consumed per
month. Regarding patients’ medication profiles, only car-
diovascularerenal drugs were documented, including
digitalis, antiarrhythmic agents, antianginal agents, anti-
hypertensive agents, b-blockers, angiotensin-converting
enzyme inhibitors (ACEI)/angiotensin II receptor blockers
(ARB), calcium channel blockers (CCB), diuretics, anti-
platelets, anticoagulants, and agents used to treat
hyperlipidemia. Therapeutic regimens (dosing, frequency,
and treatment duration) of each medication were recor-
ded in the CRF database.Table 1 Types of drug-related problems [modified from the
Classification for Drug-Related Problems, Version 5.01, 2006].
Primary Domaina Code Descri
1. Adverse reactions 1.1 Nonall
1.2 Allergi
2. Drug choice problemb 2.1 Contra
2.2 No cle
2.3 No dru
2.4 Inappr
3. Dosing problem 3.1 Drug d
3.2 Drug d
4. Interactions 4.1 Potent
4.2 Manife
5. Othersc 5.1 Insuffi
(possib
5.2 Therap
5.3 Need f
labora
a The primary domain of “drug use problems (drug not taken or adm
b Codes for inappropriate drug and inappropriate drug form were e
c Codes relevant to patients’ subjective complaints, such as “patien
excluded. Moreover, a new category, “the need for laboratory tests”DRP classification and identification
A clinical pharmacist retrospectively reviewed CRFs
completed by case managers and generated a cumulative
record for individual patients’ current and previous pre-
scriptions of key therapeutic agents. All information was
analyzed; the clinical pharmacist made inquiries of the
case manager through e-mail or phone contact, if neces-
sary. The DRPs were defined according to the definition of
the Pharmaceutical Care Network Europe Foundation
(PCNE): “An event or circumstance involving drug therapy
that actually or potentially interferes with desired health
outcomes.”16 Identified DRPs were classified using the PCNE
Classification for Drug-Related Problems. Although the
newest version is 6.2, only Version 5.0116 was available
during the study period. When applying this classification
system to study participants, we identified several prob-
lems and made modifications to ensure that this classifi-
cation system was applicable to our study. Because clinical
pharmacists did not provide a medication appraisal to
prescribers nor directly contact patients during the review
of CRP, the medication compliance of patients could not be
comprehensively identified. Therefore, DRP codes such as
drug choice problems (inappropriate drug; inappropriate
drug form) and drug use problems (drug not taken or
administered; wrong drug taken or administered) were
excluded. Codes relevant to patients’ subjective com-
plaints, such as “patients dissatisfied with therapy despite
taking drug(s) correctly,” were also excluded. Moreover, we
anticipated that clinical pharmacists would play critical
roles in monitoring the therapeutic and toxic effects of
patients’ medication regimen, which could be evaluated by
assessing laboratory parameters. For this purpose, we
introduced a new category, the need for laboratory tests, in
the primary domain “Others.” Table 1 lists the modified
DRP classification system used in this study. Domains andPharmaceutical Care Network Europe Foundation (PCNE)
ption
ergic side effects suffered
c side effects suffered
indication
ar indication for drug use
g prescribed but clearly indicated
opriate duplication of therapeutic group or active ingredient
osage too low or dosage regimen not frequent enough
osage too high or dosage regimen too frequent
ial interaction
st interaction
cient awareness of health and disease
ly leading to future problems)
y failure
or laboratory tests (e.g., therapeutic drug monitoring,
tory value, electrocardiography)
inistered; wrong drug taken or administered)” was excluded.
xcluded in the primary domain of “drug choice problem”.
ts dissatisfied with therapy despite taking drug(s) correctly” was
, was introduced in the primary domain of “Others”.
Table 2 Characteristics of the study population
(n Z 141).
Variable
Demographic
Age (y) 63.5  13.5
Male (%) 61
Clinical
NYHA functional class I/II/III (%) 1.3/32.1/65.4
LVEF (%) 39.2  16.3
Diabetes (%) 46.2
Dyslipidemia (%) 43.6
Hypertension (%) 82.1
Atrial fibrillation (%) 24.4
Cerebrovascular disease (%) 9.0
Chronic kidney disease (%) 26.9
Medication treatment (mo) 17.6  2.9
LVEF Z left ventricular ejection fraction; NYHA Z New York
Heart Association.
338 W.-T. Hsu et al.categories of the proposed DRP classification system,
including adverse reactions, dosing problems, interaction
problems, and the need for laboratory tests, were assessed
using the MICROMEDEX (Thomson Reuters) health care se-
ries software. The identified DRPs were discussed at a
multidisciplinary team meeting with the participation of
cardiologists, nurses, and clinical pharmacists.
DRP incidence rate calculation and variable
definition
Whenever the clinical pharmacist identified a DRP, the drug
class, DRP code, and time of occurrence were simulta-
neously recorded. All the recorded DRPs were categorized
according to the time at which they were identified:
3 months, 3e6 months, 6e12 months, or >12 months
within the entire enrollment period. Regarding DRP Code
4.1 (potential interaction) identified for the combination of
any two drug classes, 0.5 DRP was counted under both drug
classes instead of 1 DRP counted under one drug class,
because it was difficult to define the drug class under which
we should record the DRP. These recorded DRPs were pro-
cessed using the following calculations (DRP Codes 2.3 “no
drug prescribed but clearly indicated” and 5.1 “insufficient
awareness of health and diseases” were excluded from this
calculation because these two DRPs occurred irrespective
of enrollment period):
1. Overall DRP incidence rate (IR) at various time
intervals
IR was calculated using the following equation:
IRZ
P141
iZ1
Ei
Mi
141
where IR: the overall DRP IR (events/mo/case)
Ei: the number of DRP events identified for case i within
the time interval
Mi: the actual number of enrolled months for case i
within the time interval
141: the total number of cases
2. DRP IR of each drug class (IRDrug) at various time
intervals
The DRP IR of each drug class was calculated using the
following equation:
IRDrugZ
PNDrug
iZ 1
ðEDrugÞi
Mi
NDrug
where IRDrug: the DRP IR of a particular drug class (events/
mo/case)
(EDrug)i: the number of DRP events of a particular drug
class identified for case i within the time interval
Mi: the actual number of enrolled months for case i
within the time interval
NDrug: the number of cases using a particular drug type
3. DRP code IR of each drug class (IRDrug, Code) at various
time intervals
The DRP code IR of each drug class was calculated using
the following equation:IRDrug; CodeZ
PNDrug
iZ 1
ðEDrug;codeÞi
Mi
NDrug
where IRDrug, Code: the IR of a specific DRP code of a
particular drug class (events/mo/case)
(EDrug, Code)i: the number of events of a specific DRP code
of a particular drug class identified for case i within the
time interval
Mi: the actual number of enrolled months for case i
within the time interval
NDrug: the number of cases using a particular drug class
4. DRP risk ratio of each drug class
The DRP risk ratio of each drug class was calculated
using the following equation:
Risk ratioZ
P141
iZ1 Ei
NDrug
where Ei: the number of DRP events identified for case i
within the time interval
141: the total number of cases
NDrug: the number of cases using a particular drug type
Results
Study population
Initially, a total of 284 HF patients were referred to
outpatient clinics in the participating hospitals and moni-
tored by nurse case managers. Subsequently, the clinical
pharmacist reviewed their CRFs and excluded patients who
were followed up for less than 1 year, including those who
expired or for whom heart transplant surgery was per-
formed within 1 year. Accordingly, 143 patients were
excluded, and only 141 participants were eligible for
further evaluation in this study. Table 2 shows demographic
Table 4 Eight most frequent drug groups or drugs asso-
ciated with drug-related problems and their risk ratios,
arranged according to the number of drug-related problems
recorded.
Drug groupa DRP,
n Z 796 (%)
Number of
patients
using the drug
Risk
ratio
ACEI/ARB 167.5 (21.0) 124 1.4
Diuretics 167.0 (21.0) 115 1.5
Warfarin 84.5 (12.5) 21 4.0
Spironolactone 80.0 (10.1) 50 1.6
b-blockers 62.5 (7.9) 97 0.6
Digoxin 55.5 (7.0) 60 0.9
Amiodarone 53.5 (6.7) 25 2.1
Statins 46.5 (5.8) 59 0.8
ACEI Z angiotensin-converting enzyme inhibitors;
ARB Z angiotensin II receptor blockers; DRP Z drug-related
problem.
a The drugs accounting for the remaining DRPs (n Z 79) are
antiplatelet agents, nitrates, and calcium channel blockers
(CCBs).
DRPs in Taiwanese HF outpatients 339and clinical data of the study population at enrollment and
during medication treatment.
DRP profiles stratified by problem domain
For the 141 clinic participants, a total of 796 DRPs were
retrospectively identified by the clinical pharmacist
throughout the study period. Table 3 shows the number
and percentage of each type of DRP. Of these, the most
frequent DRPs detected were the need for laboratory
tests (Code 5.3, 32.7%), followed by potential interaction
(Code 4.1, 29.6%), nonallergic side effects (Code 1.1,
13.3%), and insufficient awareness of health and disease
(Code 5.1, 9.5%).
DRP profiles stratified by medication category
Of the 11 medication categories, the principal drugs asso-
ciated with DRPs were ACEI/ARB (21%) and diuretics (21%),
followed by warfarin (12.5%), spironolactone (10.1%), and
b-blockers (7.9%), as shown in Table 4, in which the number
of patients using each drug class is also listed for compar-
ison. ACEI/ARB and diuretics both ranked first among all
drug classes; this was likely because the proportion of pa-
tients using these two drug classes was dominant (124 and
115 of 141, respectively). Despite patients using warfarin
being in the minority (21 of 141), warfarin-related DRPs
ranked third among all drug classes. Therefore, we esti-
mated the drug risk ratio, for which the index was the
number of DRPs in relation to how often the drug was
prescribed. As expected, warfarin had high risk ratios for
DRPs. Amiodarone was another drug that was less used but
exhibited a high risk ratio.
Overall DRP IR at various time intervals
During the 2-year study period, the average time of
medication use for the 141 participants was 17 months.Table 3 Drug-related problem code distribution among study p
Primary Domain Code Description
1. Adverse reactions 1.1 Nonallergic side effects
1.2 Allergic side effects suf
2. Drug choice problem 2.1 Contraindication
2.2 No clear indication for
2.3 No drug prescribed but
2.4 Inappropriate duplicati
3. Dosing problem 3.1 Drug dosage too low or
3.2 Drug dosage too high o
4. Interactions 4.1 Potential interaction
4.2 Manifest interaction
5. Others 5.1 Insufficient awareness
(possibly leading to fut
5.2 Therapy failure
5.3 Need for laboratory tes
laboratory value, elect
TotalDespite the involvement of nurse case managers in HF
patient care, DRPs were still detected by the clinical
pharmacist throughout the entire study period, as shown
in Figure 1. This finding indicates that the inclusion of only
physicians and case managers is not sufficient to prevent
DRPs. The highest DRP IR was reported during the first
3 months (0.5 events/mo/case), implying that interven-
tion by clinical pharmacists may be required primarily at
the early stage of patient follow up. Furthermore,
although the DRP IR gradually declined and became steady
over time, DRPs were persistently registered in CRF in the
following time frames of the study. This result suggests
that clinical pharmacists play critical roles in detecting
and resolving DRPs even during long-term medication
treatment.articipants.
n (%)
suffered 106 (13.3)
fered 0 (0)
0 (0)
drug use 0 (0)
clearly indicated 56 (7.0)
on of therapeutic group or active ingredient 6 (0.8)
dosage regimen not frequent enough 33 (4.1)
r dosage regimen too frequent 12 (1.5)
236 (29.6)
11 (1.4)
of health and disease
ure problems)
76 (9.5)
0 (0)
ts (e.g., therapeutic drug monitoring,
rocardiography)
260 (32.7)
796 (100)
Figure 1 Overall drug-related problem incidence rate (IR) at
various time intervals of follow up.
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intervals
Although the overall IR of DRPs tends to be high during the
initial 3 months of medication treatment, whether tempo-
ral changes in DRP IRs differ among all drug classes was
unclear. Therefore, we selected the five most common
offending drug classes to analyze the relationship between
DRP IRs and the time frames of the study. Throughout the
entire follow-up period, IRWarfarin was highest among all five
drug classes at all time intervals. A time-dependent decline
in IRWarfarin was observed. For ACEI/ARB, b-blockers, and
spironolactone, only a minor time-dependent decline was
observed. A unique pattern was observed for diuretics; the
highest IRDiuretics was observed at 3e6 months rather than in
the first 3 months (Figure 2).DRP IR of each drug stratified by problem domain
(IRDrug, Code) at various time intervals
We next determined the DRP IRs stratified by problem do-
mains of the aforementioned five drug classes at various
time intervals. Because the predominant types of DRP wereFigure 2 Drug-related problem incidence rate of various
drug classes (IRDrug) at various time intervals of follow up.
ACEI/ARBs Z angiotensin-converting enzyme inhibitors/
angiotensin II receptor blockers.the need for laboratory tests (Code 5.3), followed by po-
tential interaction (Code 4.1), nonallergic side effects
(Code 1.1), and insufficient awareness of health and dis-
ease (Code 5.1), these four codes (1.1, 4.1, 5.1, and 5.3)
were chosen to delineate dynamic changes, as shown in
Figure 3. On the basis of this analysis, the following main
points can be summarized: first, no specific problem
domain was observed throughout the entire study period
among all drug classes. Second, the distribution patterns of
DRPs caused by each problem domain for each drug were
diverse. For ACEI/ARB, the growth and decline in IRs of all
forms of DRPs changed over time. For diuretics, IRDiuretics,
5.3 was present after 3 months of enrollment. For spi-
ronolactone, IRSpironolactone, 4.1 peaked during the first
3 months; a major decline was observed, but thereafter
remained stable. For warfarin, the highest IRWarfarin, Code for
Codes 1.1, 4.1, and 5.3 were all identified during the first
3 months. For b-blockers, a prototypic pattern was
observed because the majority of DRPs were concentrated
during the first 3 months. Finally, although warfarin is
notorious for its complicated drugedrug interactions,17,18
the occurrence of DRPs caused by such interactions was
lower than that of other forms of DRP. The most prevalent
DRP was attributed to the potential interaction of spi-
ronolactone with other drugs.Discussion
In this study, a wide variety of DRPs were encountered in HF
outpatient clinics in general hospitals.When using the slightly
modified version of the widely recognized classification sys-
tem proposed by the PCNE, we reported up to 796 DRPs in 141
clinic participants under case management of nurse special-
ists. To the best of our knowledge, our study is the first to
evaluate all aspects of DRPs, including types, IRs, and tem-
poral profiles, in outpatient HF care settings. This study em-
phasizes the advantage of a nurse case manager registering
DRPs inCRF.Becauseofcontinualhigh-intensitymonitoringby
casemanagers, clinical pharmacistswereable todetectmany
DRPs that would otherwise have been overlooked if a routine
medical chart review had been applied.
This study has several critical clinical implications. First,
HF outpatients suffer several DRPs despite the inclusion of
a nurse specialist in patient care. HF nurse specialists may
focus on the HF syndrome and its treatment and underes-
timate other comorbidities. However, when a pharmacist
reviews medication history and assesses the totality of the
drugs taken, he or she can identify medication issues
beyond HF in these patients. Therefore, the inclusion of a
pharmacist in the multidisciplinary team may facilitate the
prevention of DRPs. Second, DRPside effects, which have been
the specific focus in most previous studies, contributed to
only one-tenth of all DRPs in this study. Less attention has
been paid to other DRPs, the detection of which would
nonetheless be equally crucial. Consistent with the findings
of our study, other researchers have also found high fre-
quencies in the need for laboratory tests,19 potential
interaction,20 and insufficient awareness of health and
disease.14 This finding supports the importance of addi-
tional roles of clinical pharmacists, who are familiar with
not only medication but also the interaction between the
Figure 3 Drug-related problem incidence rate of each drug stratified by problem domain (IRDrug, Code) at various time intervals of
follow up. Time interval (mo) is depicted on the x-axis; IRDrug, Code (events/mo/case) is depicted on the y-axis. ACEI/
ARBs Z angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers.
DRPs in Taiwanese HF outpatients 341drug response and the disease. Third, the majority of DRPs
occurred during the first 3 months of patient enrollment,
whereas others occurred during the long-term follow-up
period. Consequently, uninterrupted pharmaceutical care
offered by clinical pharmacists is recommended for HF
outpatients receiving long-term pharmacotherapy. Finally,
a high risk ratio for an agent, such as warfarin or amio-
darone in this study, to cause DRP indicates that meticulous
attention is required when it is used in clinical practice.
Few studies have specifically described the temporal
changes in the occurrence of the major DRP types among
various medication categories. A pharmacist-based medi-
cation review for Taiwanese geriatrics found an increase in
the number of detected DRPs from baseline to 12 weeks
after the initial medication evaluation.20 In this report,
although the overall IR of DRPs tends to be high during the
first 3 months of medication treatment, in the subsequent
stages of prescription refills, some drug classes were found
to frequently cause certain types of DRP. For example,
diuretics were commonly associated with the need for
laboratory tests during the ensuing treatment. Therefore,
on the basis of biochemistry data, the need for dose
adjustment and discontinuation of diuretics should be
regularly monitored. Potential interaction was prevalentfor spironolactone in this study, implying that heightened
awareness is required for hyperkalemia when using the
combination of spironolactone and ACEI/ARB.21 In sum-
mary, the diverse patterns of various DRPs for each drug
class imply the complexity of long-term medication use in
HF outpatients. In these circumstances, a comprehensive
medication review must be performed to detect various
types of DRPs.
The total number of DRPs varies among studies
depending on the methods used. Consistent with other
studies, we identified at least one DRP in most participants
after careful review.20,22e24 The relatively high average of
5.6 DRPs per patient in this study implies the need for
adequate medication management in these HF outpatients.
Nonetheless, one medication may cause more than one
DRP, with some of them being dependent on each other. For
example, a given drug may cause an interaction, as a result
of which a patient may suffer a side effect, and monitoring
the drug in laboratory tests may also be required. Thus,
three DRPs can be counted. For the patient, however, only
one problem exists: the drug itself. Consequently, we
studied only the prevalence of potential DRPs instead of
actual DRPs. Whether patients with more potential DRPs
had worse clinical outcomes during follow up remained
342 W.-T. Hsu et al.unclear. Therefore, future studies should assess DRP
severity in relation to the patient and the clinical effect of
intervention by the pharmacist.
This study had certain limitations because of its retro-
spective character. Reviewing the CRF database to identify
DRPs may have resulted in the recording of “artificial”
DRPs. Moreover, information on the patients’ compliance
was not included. We could not determine the extent to
which negative clinical outcomes were avoided through
identification and treatment of DRPs. Hence, the clinical
significance of the detected DRPs could not be established.
Further evaluation of the practical implementation of the
recommendations should be conducted. In addition, the
study excluded patients who were not expected to survive
for 1 year or scheduled for heart transplantation within
1 year. Therefore, the results could not be applied to these
two populations.
Optimal medication in HF outpatients remains a major
challenge in clinical practice. This report provides evidence
that HF outpatients have a high incidence and wide variety
of DRPs despite the inclusion of a nurse specialist for case
management. We also demonstrated that a clinical phar-
macist is very helpful in the detection of DRPs, which is an
unmet medical need in our clinical practice. The effec-
tiveness of integrating a clinical pharmacist in the multi-
disciplinary HF management program should be
prospectively evaluated and emphasized in Taiwan.Acknowledgments
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